18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. - Wikidata - wikimedia - TriplyDB

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.

http://www.wikidata.org/entity/Q42945648

about

18F PET ligands for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)Untangling tau imaging Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT Imaging Multimodalities for Dissecting Alzheimer's Disease: Advanced Technologies of Positron Emission Tomography and Fluorescence Imaging Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015 The relevance of beta-amyloid on markers of Alzheimer's disease in clinically normal individuals and factors that influence these associations Brain imaging in Alzheimer disease Harmonized diagnostic criteria for Alzheimer's disease: recommendations Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease Development of positron emission tomography β-amyloid plaque imaging agents 18F-florbetaben Aβ imaging in mild cognitive impairment Spreading of pathology in neurodegenerative diseases: a focus on human studies Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis Contributions of academic laboratories to the discovery and development of chemical biology tools Quantitative amyloid imaging using image-derived arterial input function Gd(3+) complexes conjugated to Pittsburgh compound B: potential MRI markers of β-amyloid plaques.Practice effects and amyloid deposition: preliminary data on a method for enriching samples in clinical trials.Advances in CNS Imaging Agents: Focus on PET and SPECT Tracers in Experimental and Clinical Use.Near-infrared fluorescent probes for imaging of amyloid plaques in Alzheimer׳s disease Associating a negatively charged GdDOTA-derivative to the Pittsburgh compound B for targeting Aβ amyloid aggregates.Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.Diagnostic utility of amyloid PET in cerebral amyloid angiopathy-related symptomatic intracerebral hemorrhage.Mild to moderate Alzheimer dementia with insufficient neuropathological changes.Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers.Positron emission tomography radioligands for in vivo imaging of Aβ plaques.Radiosyntheses using fluorine-18: the art and science of late stage fluorination Imaging approaches for dementia.Brain imaging in the study of Alzheimer's disease Regional Fluid-Attenuated Inversion Recovery (FLAIR) at 7 Tesla correlates with amyloid beta in hippocampus and brainstem of cognitively normal elderly subjects.PET/SPECT imaging agents for neurodegenerative diseases.Dynamic PET and SPECT imaging with radioiodinated, amyloid-reactive peptide p5 in mice: a positive role for peptide dehalogenation.Imaging Brain Metabolism and Pathology in Alzheimer's Disease with Positron Emission Tomography.Evaluation of [(11)C]N-Methyl Lansoprazole as a Radiopharmaceutical for PET Imaging of Tau Neurofibrillary Tangles.The role of molecular imaging in the diagnosis and management of neuropsychiatric disorders.Amyloid imaging and memory change for prediction of cognitive impairment.In vivo optical signatures of neuronal death in a mouse model of Alzheimer's disease.Novel plasma biomarker surrogating cerebral amyloid deposition.[F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aβ antibody treatment.A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis

P2860

Q26472008-590C0AA5-C2BB-40BE-92E8-6745DF568F3E Q26739091-759DAA36-B56D-4D20-8F5A-C09A12108D1A Q26749755-3161AB3C-71D8-47AC-A063-C5A809D3E0B6 Q26770766-980208B2-44D8-4551-9E40-8F3EFD0A8633 Q26783306-FAC00B9F-E741-4E9C-837E-B0B479C897F8 Q26801654-CE1EF235-4F9E-4FB3-8151-C20F7CC781C1 Q26830467-B45FBE43-B713-4215-B948-D7FF8B44046C Q26996299-4B58AA50-89EA-48EA-9244-A4A113BDA672 Q27009157-DC47A98E-D6AC-48FC-9ED2-93C26F71EA3E Q27009411-F875197C-D6A0-4F3B-BF81-85F06DACE825 Q27012742-3E4A2028-C6BC-43FE-BF40-B2475E699213 Q27499311-6ED12C3B-3975-4FB9-8607-0F15E4EB3AE3 Q28082279-06E06BB4-B396-4D5A-B4D1-0EC8ECB8985E Q28088506-5ED95032-23AB-4380-9855-AF4561E0CD71 Q28389188-76162775-6D1E-41EB-8842-6ECDFA3C6572 Q28545789-AAF18569-AE00-4932-8778-9AF3B90D389B Q30706028-ABE38374-ADEA-4D32-BC40-87B4E6C006E5 Q30774130-5595FA35-E87E-4BB7-813F-DBC3ED3F41F0 Q30945416-48FC7323-8F4C-4487-A855-2CD95D5A5FB0 Q31025427-9D675EFE-3C33-483C-BAA2-14BD57F2A813 Q31028845-5B7933B8-C923-4444-AD3E-5B7A7DB17550 Q33556068-884CD786-57EE-45D2-8710-05795ADA5BDD Q33581237-44E3A132-2A04-465D-A435-A3CA9E441F9E Q33592693-F0021229-9CC5-49B5-8F28-CF4D33BD4113 Q33747987-E33F6FCC-788B-4490-8AF4-19474AD37EC6 Q33874024-85C297AD-1C11-4E2C-B085-913EF73A1A3C Q34074437-2D3EA094-257D-4F9C-A9FC-C98688867FC4 Q34089121-2819A000-A28D-4B75-9896-3E9D677F9165 Q34102331-BA79F2DC-179B-4512-9C06-AB73E1954461 Q34154830-27C287E3-BA84-4410-B35C-B8469260BE09 Q34156602-EEED444E-0834-4B6F-BC51-7D56CDCB1D12 Q34216798-590EA1C9-EDD9-4F21-B03B-3B3BEE880339 Q34378321-88601212-C247-4072-9D24-E9C8604C1717 Q34423050-665FC26A-8504-4575-B774-64C8A0C39F0A Q34897526-DE822C13-C970-4E96-8594-27A1F9C286E1 Q35029095-976BEE66-6691-4719-9310-0590F2C15441 Q35055819-2B401F11-1338-4E4F-82C8-CAE31A8DA1AA Q35074431-98781EAA-94AD-4C62-855D-AE7F251B70C4 Q35131160-35460827-A464-4818-8009-9F85A24D2B75 Q35158547-95D05069-BD10-4207-9FFF-05F6224DEDB3

P2860

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.

http://www.wikidata.org/entity/Q42945648

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

18F-flutemetamol amyloid imagi ...... e impairment: a phase 2 trial.

@en

18F-flutemetamol amyloid imagi ...... e impairment: a phase 2 trial.

@nl

type

label

18F-flutemetamol amyloid imagi ...... e impairment: a phase 2 trial.

@en

18F-flutemetamol amyloid imagi ...... e impairment: a phase 2 trial.

@nl

prefLabel

18F-flutemetamol amyloid imagi ...... e impairment: a phase 2 trial.

@en

18F-flutemetamol amyloid imagi ...... e impairment: a phase 2 trial.

@nl

P1433

Q42945648-6DD57D2B-56CD-48CC-874E-FDE6802BB9A3

P1476

Q42945648-9E856D34-23D6-40F5-AD41-113C09B8E867

P2093

Q42945648-1B5450F0-FCD5-45AB-B42F-BA5B0A5A15F0

Q42945648-228CCDB1-1297-42C3-A99F-7B05048D5389

Q42945648-4A03744A-F374-44C1-9E74-4F0985E5F1F5

Q42945648-550747C4-7876-493E-A0BB-321F36ECE680

Q42945648-62E261B8-C747-4DCB-99E0-C82CD7630F5F

Q42945648-8BC2C87A-F902-450A-9635-87A8EBD1390B

Q42945648-987D891F-8361-40FD-A394-A013248C5C0C

Q42945648-BD9CB7FB-B474-4EC1-B57B-F6C179361B7E

Q42945648-D410EA95-D022-4294-8C69-EE6FED55C7F3

Q42945648-F931A08D-9FC6-4D2D-8AD0-FB80D6C8F296

P2860

Q42945648-0A6B99D3-5EC3-4F58-9632-CB446CF4049D

Q42945648-0F0D333F-0F83-433E-BAFE-47EDE7E24021

Q42945648-1695D1D0-00FA-46B0-868F-9A2D2DF91B8F

Q42945648-1A9751DC-3E65-4760-8F7F-307A256CA3A7

Q42945648-26ED8872-DDB2-4970-BD72-4F54B46F2E74

Q42945648-30E7A8DD-FD3B-4E1A-8D95-269D196DAA0B

Q42945648-396C5F7C-36E7-45AE-80BE-5A55FDE70CF8

Q42945648-4A95C794-A456-48F5-BB99-570AB6302434

Q42945648-4AC9EC00-2D3B-4AAD-905F-2CA45261A264

Q42945648-630CAD74-229C-41A2-A9CE-1C2CBD895B58

P304

Q42945648-C030E81A-6A8D-476A-B8F8-939ACEA0A9F1

P31

Q42945648-55CF793D-4D81-4139-85FD-4E811B85A192

P356

Q42945648-D18DDB20-F8E8-4E35-91E7-193F900C9A4D

P433

Q42945648-EDB4AD63-452E-4403-B460-4E809F6D6C85

P478

Q42945648-89CE3CCE-3D5F-497A-82C5-1DFF4E1552BA

P50

Q42945648-36DAAC63-1441-4F8F-A17E-1AEC88C86678

Q42945648-4094C24A-95A4-4016-8366-BA7C88FE4E73

Q42945648-92FE343F-E7ED-4BB8-9EA3-FD30845AB23F

Q42945648-AB3FB2D4-1601-4DDE-AB9C-FCBF102B3850

Q42945648-B5BEE4AD-DD33-4A68-9469-0D7DB876D3FE

Q42945648-CD156DB1-DB15-45DF-B43F-469D2B62A90C

Q42945648-E5320546-0119-4412-AC0E-E25CF9027861

Q42945648-E7BB867C-54D0-491A-BFB8-C9387D179FAF

P577

Q42945648-F25ECB88-AB1D-4083-8843-9FB42A8AB79B

P698

Q42945648-C4F92709-A588-4E4A-9EDA-B1650624BDD0

P921

Q42945648-67B0040F-3118-4A81-891E-05F23FABE210

Q42945648-8F7FD270-49BB-4383-B373-24BC1A92B6D8

Q42945648-9ADB8579-9DD5-405D-BB67-5B52EF3BA13F

P356

P1433

Annals of Neurology

P1476

18F-flutemetamol amyloid imagi ...... e impairment: a phase 2 trial.

@en

P2093

Adrian Ivanoiu

http://www.w3.org/2001/XMLSchema#string

Alex Korner

http://www.w3.org/2001/XMLSchema#string

Allan Andersen

http://www.w3.org/2001/XMLSchema#string

Chris Buckley

http://www.w3.org/2001/XMLSchema#string

Eric Triau

http://www.w3.org/2001/XMLSchema#string

Gill Farrar

http://www.w3.org/2001/XMLSchema#string

Guy Bormans

http://www.w3.org/2001/XMLSchema#string

Koen Van Laere

http://www.w3.org/2001/XMLSchema#string

Lennart Thurfjell

http://www.w3.org/2001/XMLSchema#string

Natalie Nelissen

http://www.w3.org/2001/XMLSchema#string

P2860

Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain

Mild cognitive impairment: clinical characterization and outcome

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia

Amyloid imaging in mild cognitive impairment subtypes.

APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.

Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease.

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

P304

319-329

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.22068

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

Steen G. Hasselbalch

David J. Brooks

Rik Vandenberghe

Christine Bastin

Gaëtan Garraux

Lennart Minthon

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20687209

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

flutemetamol F-18

phase II clinical trial